It started with a simple question. Why doesn’t the development of new drugs look more like the design of new silicon chips? After all, no electronics company would risk the expense involved in building a new chip without first validating the design through simulation. So why does the pharmaceutical industry still depend on the trial and error method—conducting trials on patients to find out how well a drug works?